Balixafortide
- Generic Name
- Balixafortide
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1051366-32-5
- Unique Ingredient Identifier
- PRC974M49B
- Background
Balixafortide is under investigation in clinical trial NCT03786094 (Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Spexis AG
- Target Recruit Count
- 432
- Registration Number
- NCT03786094
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Fresno, California, United States
🇺🇸Tallahassee Memorial HealthCare, Tallahassee, Florida, United States
🇺🇸West Virginia University Hospital, Morgantown, West Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath